Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma on 20 september 2023 at 10 AM.
Ascelia Pharma has now completed the plan for the required re-evaluation of SPARKLE images. In the new plan, headline results from SPARKLE are expected by May 2024.
Read full announcement here: https://www.ascelia.com/mfn_news/ascelia-pharma-to-reach-headline-results-from-sparkle-re-evaluation-by-may-2024-with-current-funding/.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 14-09-2023 3.23PM.